Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A7QN
|
||||
| Former ID |
DIB002916
|
||||
| Drug Name |
Moxisylyte
|
||||
| Synonyms |
Thymoxamine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Erectile dysfunction [ICD9: 302.72, 607.84; ICD10:F52.2, N48.4] | Approved | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H26ClNO3
|
||||
| Canonical SMILES |
CC(C)c1cc(OC(=O)C)c(C)cc1OCCN(C)C
|
||||
| InChI |
1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3
|
||||
| InChIKey |
VRYMTAVOXVTQEF-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Alpha-1D adrenergic receptor | Target Info | Modulator | [2], [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Vascular smooth muscle contraction | |||||
| Salivary secretion | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Reactome | Adrenoceptors | ||||
| G alpha (q) signalling events | |||||
| G alpha (12/13) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.